Eczema (Atopic Dermatitis) Clinical Trials in Detroit
View 112 new treatments for Eczema (Atopic Dermatitis) in Detroit, MI, and nearby areas, such as Sterling Heights. Every day, Power helps hundreds of eczema patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Abrocitinib for Eczema
Research Clinic, Auburn Hills + 1 more
This trial tests abrocitinib, a medication taken regularly, on people with atopic dermatitis who didn't respond well to another treatment or have facial redness. It works by reducing inflammation. Abrocitinib is approved in Europe, the United States, and other countries for the treatment of atopic dermatitis in adults whose disease is not controlled with other treatments.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 5 - 8 Weeks
Robert Bissonnette, MD
Principal Investigator
Dupilumab for Atopic Dermatitis
Research Clinic, Ann Arbor + 1 more
Previous research has shown that Asian and African Americans are more likely to develop atopic dermatitis (AD) than their Caucasian counterparts. However, limited information is known about AD in Asian and African American populations because most molecular studies have focused on Caucasians with AD. This trial will determine differences in inflammatory responses to dupilumab between Caucasian, Asian, and African American patients with AD. The central hypothesis of this study is that ethnic differences in both immune and stromal cells contribute to variability in AD presentation and response to anti-interleukin-4 receptor (IL-4R) inhibition with dupilumab.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 6 - 12 Weeks
Johann Gudjonsson, MD
Principal Investigator
Dupilumab for Eczema
Regeneron Clinic, Dearborn + 4 more
This trial is testing a medication for treating eczema in people with skin of color. Eczema causes itchy, dry, and cracked skin. The medication aims to reduce these symptoms by calming the immune system. The study will also look at side effects, how much of the drug is in the blood at different times, and improvements in quality of life and mental health.Show More
Waitlist
No Placebo Trial
Phase 4
Est. 3 - 6 Weeks
Clinical Trial Management
Study Director
Nemolizumab for Eczema
Galderma Clinic, Detroit + 7 more
Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description
Waitlist
No Placebo Trial
Phase 3
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team
Lebrikizumab for Eczema
Eli Lilly Clinic, Troy + 2 more
This trial will test the safety and effectiveness of lebrikizumab in people with severe eczema who have already tried another treatment called Dupilumab. Lebrikizumab aims to reduce skin inflammation by blocking a protein that causes it.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 6 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Upadacitinib + Topical Corticosteroids for Eczema
AbbVie Clinic, Chesterfield + 2 more
The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.Show More
Waitlist
Phase 3
Est. 5 - 8 Weeks
ABBVIE INC.
Study Director
Rocatinlimab for Eczema
Amgen Clinic, Detroit + 1 more
This trial is testing a new medication called rocatinlimab to see if it works well and is safe when used alone. It targets patients who might benefit from a new treatment option.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
MD
Study Director
Tralokinumab for Atopic Hand Eczema
LEO Clinic, Detroit + 1 more
The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. This will be judged by a range of assessments that rate the severity and extent of atopic hand eczema and its symptoms, as well as general health status and quality of life. The trial will last for up to 40 weeks. There will be up to 15 visits, 3 of which will be conducted by phone. The first part of the trial is called a screening period and will last up to 4 weeks. For the first 16 weeks after screening, trial participants will receive either tralokinumab or dummy injections every two weeks. After the first 16 weeks, all trial participants will receive tralokinumab injections every two weeks for 16 weeks. The last part of the trial is a period of 4 weeks after the end of treatment period, where trial participants are off the drug for safety follow-up.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Medical Expert
Study Director
Abrocitinib for Atopic Dermatitis/Eczema
Pfizer Clinic, Detroit + 5 more
This trial is testing a pill called Abrocitinib to help people aged 12 and older with severe eczema. It aims to see if the pill can reduce inflammation and itching by blocking certain body chemicals. The study includes patients who have already participated in a related study.Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
Pfizer CT.gov Call Center
Study Director
Lebrikizumab for Eczema
Eli Lilly Clinic, Clarkston + 5 more
This trial is testing the safety and effectiveness of lebrikizumab, a medication for eczema. It targets people with moderate-to-severe atopic dermatitis, including those from previous studies and new participants. Lebrikizumab works by blocking a protein that causes inflammation and itching.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 5 - 8 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Page 1 of 6
Frequently Asked Questions
Explore related conditions